key: cord-0316604-2dan2oqh
authors: Xia, Hongjie; Zou, Jing; Kurhade, Chaitanya; Cai, Hui; Yang, Qi; Cutler, Mark; Cooper, David; Muik, Alexander; Jansen, Kathrin U.; Xie, Xuping; Swanson, Kena A.; Shi, Pei-Yong
title: Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine
date: 2022-01-22
journal: bioRxiv
DOI: 10.1101/2022.01.21.476344
sha: a0dc429e80153120f56f5d892f7e9faf8619bbe8
doc_id: 316604
cord_uid: 2dan2oqh

We report the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2 mRNA vaccine. Vaccinated individuals were serially tested for their neutralization against wild-type SARS-CoV-2 (strain USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. Plaque reduction neutralization results showed that at 2 or 4 weeks post-dose-2, the neutralization geometric mean titers (GMTs) were 511 and 20 against the wild-type and Omicron-spike viruses, respectively, suggesting that two doses of BNT162b2 were not sufficient to elicit robust neutralization against Omicron; at 1 month post-dose-3, the neutralization GMTs increased to 1342 and 336, respectively, indicating that three doses of vaccine increased the magnitude and breadth of neutralization against Omicron; at 4 months post-dose-3, the neutralization GMTs decreased to 820 and 171, respectively, suggesting similar neutralization decay kinetics for both variants. The data support a three-dose vaccine strategy and provide the first glimpse of the neutralization durability against Omicron.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and generates new variants of concern (VOCs), including Alpha, Beta, Gamma, Delta, and Omicron.

Variant mutations, particularly those in the spike glycoprotein, can alter viral transmission, disease severity, therapeutic antibody efficacy, and potentially vaccine effectiveness. The newly emerged Omicron variant (B.1.1.529 lineage) was first detected in South Africa, reported to WHO on November 24 th , 2021, and designated as a VOC two days later. It is rapidly spreading around the world and causing increased breakthrough infections in previously infected and vaccinated individuals. 1 Laboratory results are urgently needed to examine vaccine-elicited neutralization of the Omicron variant and the duration in which this activity persists.

BNT162b2, an mRNA vaccine that encodes the prefusion stabilized full spike glycoprotein of SARS-CoV-2 isolate Wuhan-Hu-1, has received regulatory approval and/or authorization around the world including approval for vaccination of people 16 years of age and older and authorization under emergency use provision for immunization of individuals 5-15 years old by the US Food and Drug Administration. We formerly reported that recombinant SARS-CoV-2 bearing spike genes from previous VOCs, variants of interest (VOIs), and variants under monitoring (VUMs) remained susceptible to BNT162b2 vaccine-elicited neutralization. While the Beta variant exhibited the most neutralization reduction among all tested variants, high efficacy against Beta was observed. 2 To determine the susceptibility of Omicron variant to BNT162b2-elicited neutralization, we engineered the complete Omicron spike into the USA-WA1/2020 genetic background (Fig. S1) . The resulting recombinant Omicron-spike SARS-CoV-2 contained spike mutations A67V, H69-V70 deletion (∆69-70), T95I, G142D, V143-Y145 deletion (∆143-145), N211 deletion (∆211), L212I, L214 insertion EPE (ins214EPE), G339D, S371L, S373P, S375F, K417N, N440K, G446S,   S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F (GISAID EPI_ISL_6640916). The recombinant Omicron-spike SARS-CoV-2 and wild-type USA-WA1/2020 produced infectious titers of greater than 10 7 plaque-forming units per milliliter (PFU/ml). The recombinant viruses were sequenced to ensure no undesired mutations. Although Omicron-spike virus formed smaller plaques than the wild-type USA-WA1/2020 (Fig. S2) , both viruses showed equivalent viral RNA genome/PFU ratios when analyzed on Vero E6 cells (Fig. S3) , suggesting comparable specific infectivities of the viral stocks.

We determined 50% plaque reduction neutralization titers (PRNT 50 ) against recombinant USA-WA1/2020 and Omicron-spike SARS-CoV-2 using four serum panels from BNT162b2vaccinated participants of the phase 1 portion of Study C4591001. The first panel contained 20 sera, collected 2 or 4 weeks after the second dose of 30 µg of BNT162b2, which was administered 3 weeks after the first immunization 2 (Fig. S4) . These post-dose-2 (PD2) sera neutralized USA-WA1/2020 and Omicron-spike SARS-CoV-2 with geometric mean titers (GMTs) of 511 and 20, respectively. All PD2 sera had neutralization titers of 160 or higher against the wildtype USA-WA1/2020, whereas only 11 of the 20 sera had neutralization titers of 20 (limit of detection) or higher against the Omicron-spike virus (Fig. 1A) . The second serum panel contained 22 specimens, collected on the day of the third 30 µg BNT162b2 dose which was administered 7.9 to 8.8 months after dose 2 3 (Fig. S4) . The GMTs against USA-WA1/2020 decreased to 65, while the GMTs against Omicron remained low at 13 (Fig. 1B) . The third and fourth serum panels were collected 1 and 4 months after the third dose, respectively (Fig. S4) . The 1-month-postdose-3 (1MPD3) sera neutralized USA-WA1/2020 and Omicron-spike SARS-CoV-2 with GMTs of 1342 and 336, respectively (Fig. 1C) . The 4-month-post-dose-3 (4MPD3) sera neutralized USA-WA1/2020 and Omicron-spike SARS-CoV-2 with GMTs of 820 and 171, respectively; all the 4MPD3 sera neutralized Omicron-spike virus at titers of 28 or higher (Fig. 1D) . Figure S5 summarizes the PRNT 50 curves for individual subjects. Collectively, the data support three conclusions. First, at 2 or 4 weeks PD2, the neutralization GMT against Omicron-spike SARS-CoV-2 was 25.6 times lower than that against USA-WA1/2020 and in a similar range of reduction noted in some preliminary and peer reviewed reports. 4 Differences in Omicron neutralization reduction compared to wild-type USA-WA1/2020 across studies are likely attributed to different serum samples, time of sampling, assay formats and assay protocols, but nonetheless support a substantial decrease in neutralization activity against Omicron after two doses of BNT162b2.

Second, by 1-month PD3, neutralization GMTs against wild-type USA-WA1/2020 and Omicronspike virus increased by 2.6 and 16.8 times, respectively, when compared to the corresponding GMTs by 2 to 4 weeks PD2. Thus, after dose 3, the increase of neutralization GMTs against the Omicron virus was 6.5 times higher than that against USA-WA1/2020. This result agrees with our recent findings that a third dose of BNT162b2 increased the magnitude and breadth of neutralization against Delta and Beta variants. 3 Third, from 1 to 4 months PD3, neutralization GMTs against USA-WA1/2020 and Omicron decreased by 1.6 and 2 times, respectively, suggesting similar antibody decay kinetics for both variants.

Our data demonstrate that three doses of BNT162b2 elicited substantial neutralization activity against Omicron-spike SARS-CoV-2, while two doses showed significantly reduced neutralization titers. The neutralization GMT against Omicron-spike virus after dose 3 (336) was close to the neutralization GMT against wild-type USA-WA1/2020 after dose 2 (511), which was previously associated with high efficacy in the pivotal efficacy study (C4591001). These data suggest that a third-dose vaccine strategy could minimize the health impact of Omicron. This is supported by initial reports demonstrating that while vaccine effectiveness against symptomatic infection due to Omicron may wane following a third dose of BNT162b2, the effectiveness against hospitalization remains high. 5 The current study has two limitations. First, the durability of the neutralization against Omicron variant beyond 4 months PD3 remains to be determined. Second, other immune effectors, such as T cells and non-neutralizing antibodies that mediate antibody-dependent cytotoxicity, have not been examined. CD8+ T cell responses likely play an important role in protection against severe COVID-19; despite the significant number of mutations in the Omicron spike, the majority of T cell epitopes of spike glycoprotein are preserved. Taken together, the current in vitro study suggests that 2 doses of BNT162b2 may remain effective against severe disease, but that a third dose of BNT162b2 is likely required to maintain effectiveness against COVID-19 caused by Omicron. Additional real world effectiveness data and laboratory investigations will further inform the duration of protection, potential need for an additional dose at a later time, and whether an Omicron modified vaccine is required.

Recombinant Omicron-spike SARS-CoV-2 was constructed by engineering the complete spike gene from Omicron variant (GISAID EPI_ISL_6640916) into an infectious cDNA clone of clinical isolate USA-WA1/2020 6 ( Figure S1 ). All spike mutations were introduced into the infectious cDNA clone of USA-WA1/2020 using PCR-based mutagenesis as previously described. 7 The full-length cDNA of viral genome containing the complete Omicron spike mutations was assembled via in vitro ligation. The resulting full-length cDNA was used as a template for in vitro transcription of genome-length viral RNA. The in vitro transcribed genome-length viral RNA was electroporated into Vero E6 cells. On day 3 post electroporation, the original viral stock (P0) was harvested from the electroporated cells. The P0 virus was propagated for another round on Vero E6 cells to produce the P1 stock for neutralization testing. The infectious titer of the P1 virus was quantified by plaque assay on Vero E6 cells ( Figure S2) . The complete spike gene of the P1 virus was sequenced to ensure no undesired mutations. The protocols for the mutagenesis of SARS-CoV-2 and virus production were reported previously. 8 For determining the specific infectivity of each virus, the P1 virus stock was quantified for its plaque-forming unit (PFU) and genomic RNA content by plaque assay on Vero E6 cells and RT-qPCR, respectively.

The methods for plaque assay and RT-qPCR were reported previously. 9 The specific infectivity of each virus was indicated by the genomic RNA-to-PFU ratios (genome/PFU).

vaccinated serum panels were used in the study. Figure S4 summarizes the collection time of serum panels. The first panel (n=20) was collected at 2 weeks (circles) or 4 weeks (triangles) after the second dose of BNT162b2. The second panel (n=22) was collected on the day of the third dose of BNT162b2, which was administered at 7.9 to 8.8 months after the second dose.

The third (n=22) and fourth (n=21) panels were collected at 1 and 4 months after the third dose, respectively. The information for the first and third serum panels were reported previously. 2, 3 The 50% plaque-reduction neutralization titer (PRNT 50 ) was measured for each serum as previously reported. 10, 11 Individual sera were 2-fold serially diluted in culture medium with a starting dilution of 1:20. The diluted sera were incubated with 100 PFU of Omicron-spike SARS-CoV-2 or USA-WA1/2020. After 1 h incubation at 37 °C, the serum-virus mixtures were inoculated onto 6-well plates with a monolayer of Vero E6 cells pre-seeded on the previous day.

The PRNT 50 value was defined as the minimal serum dilution that suppressed >50% of viral plaques. The neutralization titer was determined in duplicate assays, and the geometric mean was taken. Table S1summarizes the PRNT 50 results for all serum samples. Table S1 . *Individual PRNT 50 value is the geometric mean of duplicate plaque assay results. PRNT 50 of < 20 was treated as 10 for plot purposes and statistical analysis. N.A.: not available. # The sera collected at 2 and 4 weeks after dose 2 were reported. 2 The sera collected at 1 month after dose 3 were also reported. 3 † Geometric mean neutralizing titers. ^9 5% confidence interval (95% CI) for the GMT.

SARS-CoV-2 variants of concern and variants under investigation in England

Neutralizing Activity of BNT162b2-Elicited Serum

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Effectiveness of 3 doses of COVID-19 vaccines against symptomatic COVID-19 and hospitalisation in adults aged 65 years and old

An Infectious cDNA Clone of SARS-CoV-2

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Engineering SARS-CoV-2 using a reverse genetic system

Spike mutation D614G alters SARS-CoV-2 fitness

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

We thank the Pfizer-BioNTech clinical trial C4591001 and NCT04368728 participants, from whom the post-immunization human sera were obtained. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine. We thank John Yun-Chung Chen and Cody Bills from the University of Texas Medical Branch at Galveston for help with plaque assays.